bioAffinity Technologies, Inc. announced the publication of a clinical review and white paper by Chief Medical Officer Gordon H. Downie, MD, PhD, which presents a clinical framework for using CyPath Lung to evaluate pulmonary nodules and cancer surveillance. The publication discusses how the test's lung microenvironment analysis via sputum collection is integrated into primary care, pulmonology, and oncology practices. bioAffinity Technologies, Inc. is a biotechnology company focused on noninvasive diagnostics and early cancer detection.
